About Contact Us Careers

Meloxicam Market Size and Forecast, by Diseases (Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis), Drug Type (Combination Drug, Prescribed Drug), Population Type (Adult, Children), Dosage (Oral, Parenteral, transdermal), Dose Strength (7.5mg, 15mg), End-Users (Hospitals, Specialty Clinics, Home Healthcare), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 5360
  • Published Date: Nov 26, 2025
  • Report Format: PDF, PPT
Festive Special Offer
$4550 $2450

Meloxicam Market Outlook:

Meloxicam Market size was over USD 7.64 billion in 2025 and is projected to reach USD 12.21 billion by 2035, growing at around 4.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of meloxicam is evaluated at USD 7.97 billion.

Meloxicam Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The growth of this market can be attributed to the back of increasing prevalence of osteoarthritis, juvenile rheumatoid arthritis, and rheumatoid arthritis especially among the old population. Meloxicam is an effective pain management medication highly used in the treatment of the above health problems. In this health issue when doctors initiate surgeries the post-surgery pain is always at a high range and is too much painful in order to offer relief from this pain to patients doctors use pain management medications such as meloxicam. Thus, the increasing incidence of these diseases is raising the demand for meloxicam market in the projected time period. As per a report by  the World Health Organization, 60% of those who have osteoarthritis are female and 73% are older than 55. The knee is the joint that is most frequently affected, with an estimated number of 365 million, next to the hip and the hand.   

Furthermore, the growth of the market can also be driven by increasing awareness about the availability of pain relief medication. In the past few times, there has been a surge in awareness about pain relief medication available in the market among the population. This is predicted to boost the market growth of meloxicam in the projection time period.

Key Meloxicam Market Insights Summary:

  • Regional Highlights:

    • North America meloxicam market is expected to hold a 33% share, attributed to the growing incidence of arthritis and chronic pain disorders.
    • By 2035, the Asia Pacific region is anticipated to secure a notable share, supported by rising demand driven by an expanding aging population and increasing cases of osteoarthritis and related conditions.

  • Segment Insights:

    • By 2035, the osteoarthritis segment in the meloxicam market is projected to command a 40% share, propelled by heightened arthritis prevalence and increased awareness of long-term joint-preserving therapies.
    • The combination drug segment is set to grow considerably by 2035, reinforced by its broadening application in treating multiple health conditions concurrently.

  • Key Growth Trends:

    • Increasing Technological Advancement
    • Increasing Prevalence of NSAIDs

  • Major Challenges:

    • Competition from other NSAIDs
    • Availability of Generic Meloxicam

  • Key Players: Healthy Life Pharma Private Limited., EPICON LIFESCIENCES LLP, Boehringer Ingelheim GmbH., Baudax Bio, Heron Therapeutics Inc., Avanstra Inc., PD-Rx Pharmaceuticals, Inc.

Global Meloxicam Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 7.64 billion
    • 2026 Market Size: USD 7.97 billion
    • Projected Market Size: USD 12.21 billion by 2035
    • Growth Forecasts: 4.8%

  • Key Regional Dynamics:

    • Largest Region: North America (33% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Germany, Japan, United Kingdom
    • Emerging Countries: India, South Korea, Brazil, Indonesia, Australia

    • Last updated on : 26 November, 2025

Growth Drivers

  • Increasing Technological Advancement – The growth of this meloxicam market can be ascribed to an increasing technological advancement taking place in meloxicam. The global growth rate of the meloxicam retail market has been accelerated by the launch of new and enhanced goods as a result of the development of fresh technologies. Furthermore, advancements in drug delivery technologies and formulations are enhancing the efficacy and safety of meloxicam making it a more appealing treatment option.
  • Increasing Prevalence of NSAIDs - Increased preference for NSAIDs over other painkillers like opioids also contributes to the meloxicam market's expansion in the anticipated time period. NSAIDs such as meloxicam are at times preferred over other painkillers such as opioids owing to their lower risk of addiction and side effects. In addition, the meloxicam market is growing as chronic inflammation and pain illnesses become more prevalent.
  • Growing Strategic Collaboration and Partnerships – Pharmaceutical companies are collaborating with research institutions and other companies to develop new formulations and applications for meloxicam. Therefore, this is accelerating the market expansion of meloxicam in the upcoming time period. 

Challenges

  • Competition from other NSAIDs – Meloxicam is one of many NSAIDs on the market, and it faces stiff competition from other drugs in its class, such as ibuprofen and naproxen. These drugs are often less expensive than meloxicam and may have a better safety profile. Therefore, high competition by other NSAIDs is expected to hamper the meloxicam market growth of meloxicam in the forthcoming years.
  • Concerns Associated with Side Effects of Meloxicam is Predicted to Restrict the Market Expansion in the Future Times
  • The Availability of Generic Meloxicam is Posing a Limitation on the Market Expansion in Forecast Period.

Meloxicam Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

4.8%

Base Year Market Size (2025)

USD 7.64 billion

Forecast Year Market Size (2035)

USD 12.21 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Meloxicam Market Segmentation:

Diseases Segment Analysis

In terms of disease, the osteoarthritis segment in the meloxicam market is estimated to account for the largest revenue share of 40% by the end of 2035. The rise in prevalence and consumer awareness of treatment options like glucosamine and chondroitin sulfate, which do not significantly reduce the signs of this medical condition but instead assist in preserving joint motion over an extended period of time, can be attributed to the growth of this market in the projected time period. A severe health emergency also includes arthritis.  According to the CDC, 53.2 million US individuals, or 1 in 4, have some kind of arthritis. There are more than 100 different forms of arthritis, but osteoarthritis, which affects 32.5 million US adults, is the most widespread.

Drug Type Segment Analysis

Meloxicam market from the combination drug segment is set to grow significantly by 2035. Combination drugs are drugs taken together to treat different conditions, and their ability to treat many diseases is the main reason for this increase in demand. For example, Vioxx is a combination drug used to treat both rheumatoid arthritis and pain; however, it caused heart problems as well as other side effects and thus fell behind in the market.

Our in-depth analysis of the global meloxicam market includes the following segments:

          Diseases

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Juvenile Rheumatoid Arthritis

          Drug Type
  • Combination Drug
  • Prescribed Drug

          Population Type
  • Adult
  • Children

          Dosage
  • Oral
  •  Parenteral
  • Transdermal

          Dose Strength
  • 7.5mg
  • 15mg

          End-Users
  • Hospitals
  •  Specialty Clinics
  • Home Healthcare

          Distribution Channel
  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Meloxicam Market - Regional Analysis

North American Market Insights

North America industry is set to account for largest revenue share of 33% by 2035, The growth of this market can be primarily driven by an increasing number of arthritis and other chronic pain disease patients found in this region. Besides, increasing healthcare infrastructure and escalating research and development activities in meloxicam are driving the market expansion further in the North America region during the projected period. An estimated 58.5 million US adults have been told by their doctor that they have some form of arthritis, rheumatoid arthritis, gout, lupus or fibromyalgia, based on data from the National Health Interview Survey between 2016 and 2018.

APAC Market Insights

The meloxicam market in the Asia Pacific region is estimated to account for a notable revenue share during the forecast period. This growth can be attributed to high product demand due to the growing aging population and the increasing incidence of osteoarthritis, rheumatoid arthritis, soft tissue inflammation, traumatic pain and post-operative pain. Also, there has been surging demand for rheumatoid arthritis treatment in the region. Additionally, regional growth over the forecast period is expected to be driven by favorable reimbursement policies for generic drugs. All these factors are predicted to drive the market growth of meloxicam in the APAC region during the studied period.

Meloxicam Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Meloxicam Market Players:

    • Taj Pharmaceutical Limited.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Wellona Pharma
    • Trumac Healthcare
    • Healthy Life Pharma Private Limited.
    • EPICON LIFESCIENCES LLP
    • Boehringer Ingelheim GmbH.
    • Baudax Bio
    • Heron Therapeutics Inc.
    • Avanstra Inc.
    • PD-Rx Pharmaceuticals, Inc.

Recent Developments

  • Baudax Bio, Inc., a pharmaceutical company specializing in acute care therapies, announced that ANJESO (meloxicam), the only 24-hour intravenous COX-2 preferred nonsteroidal anti-inflammatory drug , is now available at command. and deliver goods to customers. ANJESO was approved by the U.S. Food and Drug Administration (FDA) on February 20, 2020, and is indicated for the treatment of moderate to severe pain, alone or in combination with other medications. Other non-NSAID pain relievers.
  • Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important needs of patients, today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults to soft tissue or periarticular drops to provide postoperative analgesia for up to 72 hours after bunionectomy, open inguinal hernia, and total knee replacement surgery.  
  • Report ID: 5360
  • Published Date: Nov 26, 2025
  • Report Format: PDF, PPT
Festive Special Offer
$4550 $2450
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of meloxicam is evaluated at USD 7.97 billion.

The global meloxicam market size was worth over USD 7.64 billion in 2025 and is poised to grow at a CAGR of around 4.8%, reaching USD 12.21 billion revenue by 2035.

North America meloxicam market is expected to hold a 33% share, attributed to the growing incidence of arthritis and chronic pain disorders.

Key players in the market include Healthy Life Pharma Private Limited., EPICON LIFESCIENCES LLP, Boehringer Ingelheim GmbH., Baudax Bio, Heron Therapeutics Inc., Avanstra Inc., PD-Rx Pharmaceuticals, Inc.

Meloxicam Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Buy Now Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos